[F-18]Flornaptitril PET — Phase 3 Tau Imaging for Alzheimer's Disease
Clinical Trial Identifier: [NCT06254469](https://clinicaltrials.gov/study/NCT06254469)
Trial Overview
Mermaid diagram (expand to render)
[F-18]Flornaptitril (also known as 18F-MK-6240) is a novel fluorine-18 labeled PET radiotracer developed by CereMark Pharma for imaging tau pathology in Alzheimer's disease and other tauopathies. This Phase 3 clinical trial evaluates its utility in predicting Alzheimer's disease progression and differentiating between various tauopathies.
This trial represents a critical step forward in precision medicine for neurodegenerative diseases, where accurate tau pathology detection enables better diagnostic stratification, prognostic counseling, and treatment selection.
| Field | Value |
|-------|-------|
| NCT Number | NCT06254469 |
| Phase | Phase 3 |
| Status | Recruiting |
| Sponsor | CereMark Pharma |
| Condition | Alzheimer's Disease, Cognitively Normal |
| Participants | 230 |
| Intervention | [F-18]Flornaptitril PET scan |
| Primary Outcome | Tau deposition quantification |
| Study Duration | 24 months |
| Imaging Timepoints | Baseline, 12 months, 24 months |
Background and Rationale
The Importance of Tau Imaging in Alzheimer's Disease
Alzheimer's disease (AD) is characterized by two hallmark protein pathologies: amyloid-beta (Aβ) plaques and neurofibrillary tau tangles (NFTs). While amyloid deposition begins decades before clinical symptoms, it is the tau pathology that more closely correlates with clinical impairment and disease progression[@devous2002].
Tau is a microtubule-associated protein that stabilizes axonal microtubules. In AD, tau becomes hyperphosphorylated, aggregates into paired helical filaments (PHFs), and forms neurofibrillary tangles within neurons. The spread of tau pathology follows a predictable pattern—beginning in the entorhinal cortex and progressing to the hippocampus and neocortex—mirroring the clinical progression of cognitive decline[@scholl2017].
Key reasons tau PET imaging is crucial:
Tau Correlates with Cognition: NFT burden correlates more strongly with cognitive impairment than amyloid burden. Studies show that regional tau deposition predicts rate of cognitive decline more accurately than amyloid measures[@cope2018].
Disease Staging: Tau PET enables in vivo staging of Alzheimer's disease, providing information about disease severity and prognosis that amyloid imaging alone cannot[@jack2018].
Differential Diagnosis: Different tauopathies have distinct regional patterns of tau deposition. AD typically shows neocortical and limbic tau, while progressive supranuclear palsy (PSP) shows basal ganglia and brainstem patterns, and corticobasal syndrome (CBS) shows asymmetric cortical involvement[@mott2016].
Therapeutic Development: Tau PET is essential for:
- Enriching clinical trials with patients who have tau pathology
- Monitoring treatment response to anti-tau therapies
- Demonstrating target engagement for tau-targeting drugs
Current Limitations of Tau PET
First-generation tau PET tracers (notably flortaucipir, also known as AV-1451 or Tauvid) have shown excellent performance in AD but face limitations:
- Off-target binding: Non-specific binding in basal ganglia and other regions
- Limited differentiation of 3R vs 4R tau: Cannot distinguish AD (mixed 3R/4R) from pure 4R tauopathies
- Blood pool artifact: High signal in vascular compartments
- Limited utility in non-AD tauopathies: Not optimized for PSP, CBD, or other 4R tauopathies
Flornaptitril was developed to address some of these limitations, with improved binding selectivity and kinetics.
Mechanism of Action
Tau PET Imaging Principles
Flornaptitril is a fluorine-18 labeled small molecule that crosses the blood-brain barrier and binds selectively to tau protein aggregates:
- Target: Hyperphosphorylated tau protein in neurofibrillary tangles (NFTs)
- Binding Site: Specific to paired helical filament (PHF) tau conformation
- Selectivity: Preferential binding to PHF over amyloid-beta plaques
- Signal Generation: F-18 emission (half-life 110 minutes) detected via PET imaging
Binding Characteristics
| Property | Flornaptitril | Flortaucipir |
|----------|-------------|-------------|
| Ki (PHF tau) | ~1 nM | ~1 nM |
| Amyloid selectivity | >10-fold | ~2-fold |
| Brain kinetics | Fast | Moderate |
| Off-target | Lower | Higher (basal ganglia) |
The Neurobiological Basis
The selective binding of Flornaptitril to PHF tau reflects the unique conformation of tau filaments in different diseases:
- Alzheimer's disease (AD): Mixed 3R + 4R tau in paired helical filaments
- Progressive supranuclear palsy (PSP): Primarily 4R tau in straight filaments
- Corticobasal degeneration (CBD): 4R tau in astrocytic plaques
- Chronic traumatic encephalopathy (CTE): 3R + 4R tau in NFTs
The ability to differentiate these conformations could enable accurate differential diagnosis, which is currently challenging clinically.
Differentiation from Other Tauopathies
One of Flornaptitril's potential advantages is the ability to help differentiate AD tau from other tauopathies:
| Tauopathy | Characteristic Tau Type | Typical Pattern |
|-----------|------------------------|------------------|
| Alzheimer's Disease | 3R/4R PHF | Entorhinal cortex → Hippocampus → Neocortex |
| Progressive Supranuclear Palsy | 4R | Basal ganglia, brainstem, cerebellar |
| Corticobasal Syndrome | 4R | Asymmetric frontoparietal cortex |
| Chronic Traumatic Encephalopathy | 3R/4R | Deep brain structures, cortex |
The ability of Flornaptitril to potentially differentiate CTE from AD is particularly significant, as current tracers cannot reliably make this distinction.
Study Design
Trial Objectives
Primary:
- Assess diagnostic performance of Flornaptitril PET for AD prediction
- Evaluate sensitivity and specificity for detecting tau pathology
- Determine optimal quantification approaches
Secondary:
- Compare with established tau PET tracers (flortaucipir)
- Assess correlation with cognitive measures (MMSE, CDR)
- Evaluate utility in differentiating AD from other tauopathies
- Establish longitudinal change metrics
Imaging Protocol
| Parameter | Specification |
|-----------|--------------|
| Dose | 185-370 MBq (5-10 mCi) Flornaptitril IV |
| Scan start | 30-40 minutes post-injection |
| Duration | 20 minutes |
| Reconstruction | OSEM with attenuation correction |
| Regions | Cortical VOIs (frontal, temporal, parietal, occipital, ACC) |
Inclusion Criteria
- Age 50-85 years
- Cognitively normal (CDR 0) or mild cognitive impairment (CDR 0.5)
- Ability to undergo PET imaging
- No significant neurological conditions (except AD)
- MMSE score ≥ 20
- Fluent in English or local language
Exclusion Criteria
- Contraindications to PET imaging (radiation allergy, claustrophobia)
- Active psychiatric conditions (major depression, psychosis)
- Significant brain pathology other than AD (infarcts, tumors)
- Current substance abuse
- Metallic implants (MRI incompatible)
Participant Stratification
The trial enrolls participants in three groups:
Cognitively Normal, Tau-negative (n=80): Control group
Cognitively Normal or MCI, Tau-positive (n=90): Preclinical/early AD
Clinical AD (n=60): Mild-to-moderate AD dementiaStudy Procedures
Baseline Visit:
- Medical and neurological examination
- Cognitive testing (MMSE, CDR, neuropsychological battery)
- MRI brain scan
- PET imaging session (90-minute dynamic scan)
- CSF collection (optional, for biomarker substudy)
Follow-up:
- Repeat PET imaging at 12 and 24 months
- Cognitive assessments at 6-month intervals
- Safety monitoring throughout
Comparison with Existing Tau PET Tracers
Current Tau PET Tracer Landscape
| Tracer | Developer | Target | Status | Key Features |
|--------|-----------|--------|--------|-------------|
| Flortaucipir (AV-1451) | Eli Lilly | PHF-tau | Approved | First approved, validated in AD |
| Flornaptitril | CereMark Pharma | PHF-tau | Phase 3 | Potential CTE differentiation |
| PI-2620 | AC Immune/Roche | 4R-tau | Phase 2 | PSP/CBD specificity |
| APN-1607 (Lifecann) | Aprinoia | PHF-tau | Phase 2 | Broader detection |
| MK-6240 | Merck | PHF-tau | Phase 2 | High specificity |
Advantages of Flornaptitril
Improved Target-to-Background Ratio: Early data suggest improved signal-to-noise compared to first-generation tracers
Broader Tauopathy Coverage: Designed to detect multiple tauopathy subtypes
CTE Differentiation: Potential to differentiate chronic traumatic encephalopathy from AD
Off-Target Reduction: Modified structure to reduce off-target bindingClinical Significance and Applications
Early Detection and Prevention
One of the most promising applications of tau PET is identifying individuals with preclinical AD:
Preclinical AD Detection:
- Cognitively normal individuals with positive tau PET have higher risk of progression to MCI/AD
- Tau PET positivity may occur before significant cognitive decline
- Enables identification of individuals who might benefit from early intervention
Risk Stratification:
- Tau burden provides information beyond amyloid for predicting progression
- Regional tau patterns indicate likely clinical phenotype
- Combined with amyloid PET, enables comprehensive pathology assessment
Differential Diagnosis
Tau PET has become essential for differentiating neurodegenerative conditions:
AD vs. Other Dementias:
- Distinguishing AD from frontotemporal dementia
- Differentiating AD from vascular dementia
- Identifying mixed pathology
Tauopathies:
- Distinguishing AD from PSP
- Differentiating AD from CBS
- Identifying primary age-related tauopathy (PART)
Clinical Trial Enrichment
Tau PET is increasingly used in clinical trials for:
Patient Enrichment: Selecting patients with confirmed tau pathology for anti-tau therapy trials
Target Engagement: Demonstrating drug binding to tau in the brain
Treatment Response: Monitoring changes in tau burden over timeSafety Considerations
Radiation Exposure
PET imaging involves exposure to ionizing radiation:
- Typical effective dose from one [F-18]Flornaptitril scan: ~5-7 mSv
- Cumulative dose from three scans over 24 months: ~15-21 mSv
- This is comparable to other nuclear medicine procedures and within safe limits
Contraindications
Absolute Contraindications:
- Pregnancy
- Breastfeeding (pause for 24 hours post-injection)
- Unable to lie still for 90 minutes
Relative Contraindications:
- Severe claustrophobia (consider open MRI)
- Metal implants that may cause artifacts
Adverse Events
[F-18]Flornaptitril has been well-tolerated in Phase 1/2 studies:
- Injection site reactions: rare
- Headache: uncommon
- Nausea: rare
- Allergic reactions: very rare
Industry Context
CereMark Pharma is a biotechnology company focused on precision diagnostics for neurodegenerative diseases. Their pipeline includes:
- Tau PET tracers: Flornaptitril (AD), subsequent candidates for PSP/CBD
- Alpha-synuclein tracers: In development for Parkinson's disease
- Companion diagnostics: For anti-tau therapeutic programs
Competitive Landscape
| Company | Tracer | Development Stage |
|--------|--------|------------------|
| CereMark | Flornaptitril | Phase 3 |
| Eli Lilly | Flortaucipir | Approved |
| AbbVie | PI-2620 | Phase 2 |
| Life Molecular | LTE | Phase 1 |
Market Impact
Tau PET imaging represents a significant market opportunity:
- Global Tau PET Market: ~$800M annually
- Growth Drivers: Alzheimer's prevalence, clinical trial demand, precision medicine
- Competitive Landscape: 5+ companies developing next-gen tau tracers
- Reimbursement: Active discussion for Medicare coverage in 2026
Participant Experience
Imaging Protocol
The Flornaptitril PET scan follows a standardized protocol:
Radiotracer Administration: ~185 MBq (5 mCi) IV injection
Scan Window: 80-100 minutes post-injection
Duration: 20-minute acquisition
Repeat: Baseline and 12-month follow-up scans
Safety Monitoring: Vital signs before and after scanParticipant Burden
- Total Time: ~2.5 hours per visit
- Radiation Dose: ~3.5 mSv per scan (comparable to CT)
- Repeat Scans: Two visits over 12 months
- Cognitive Testing: Included in each visit (~45 minutes)
Future Directions
Integration with Multi-modal Biomarkers
Flornaptitril PET is designed to work alongside:
- Amyloid PET (Pittsburgh compound B): Confirms amyloid pathology
- FDG-PET: Assesses glucose metabolism
- MRI: Structural anatomy
- CSF biomarkers: Tau, amyloid protein levels
- Blood-based biomarkers: Promise for screening
Combined Scoring Systems
The integration of multiple biomarkers enables:
- AT(N) classification: Amyloid, Tau, Neurodegeneration system
- Biological definition of AD: Amyloid + tau pathology
- Stage-appropriate interventions: Match treatment to disease stage
Post-Trial Research Opportunities
Regardless of trial outcome, this research will inform:
Optimal Imaging Protocols: Determining ideal scan timing and analysis methods
Quantitative Metrics: Standardizing SUVR measurements and cutoff values
Longitudinal Changes: Characterizing tau accumulation rates in different populationsCurrent Status
This trial is actively recruiting. For more information:
- ClinicalTrials.gov: [NCT06254469](https://clinicaltrials.gov/study/NCT06254469)
- CereMark Pharma: www.cermarkpharma.com
- Contact: clinicaltrials@cermarkpharma.com
Technical Specifications
Radiotracer Properties
| Property | Value |
|----------|-------|
| Radioisotope | Fluorine-18 |
| Half-life | 109.7 minutes |
| Production | Cyclotron |
| Specific activity | >100 GBq/μmol |
| Formulation | Sterile solution for IV injection |
Imaging Protocol
PET Acquisition:
- Dynamic scan for 90-120 minutes
- Standardized uptake value (SUV) calculations
- Distribution volume (VT) modeling
MR Reference:
- T1-weighted MRI for anatomical segmentation
- Atrophy correction for partial volume effects
Competitive Landscape
Tau PET Tracer Comparison
| Tracer | Target | 3R/4R Specificity | FDA Status | Key Limitation |
|--------|--------|-------------------|------------|----------------|
| Flortaucipir (AV-1451) | PHF tau | Mixed | Approved (AD) | Off-target binding |
| Flornaptitril | PHF tau | Mixed | Phase 3 | CTE differentiation |
| PI-2620 | 4R tau | 4R-specific | Phase 2 | Limited AD signal |
| MK-6240 | PHF tau | Mixed | Phase 3 | Unknown |
| JNJ-068 | 4R tau | 4R-specific | Phase 1 | Early development |
Market Opportunity
The global tau PET imaging market is projected to grow significantly:
- Current AD diagnostics rely heavily on amyloid PET
- Tau PET provides superior correlation with cognitive decline
- Differential diagnosis remains unmet need
- Clinical trial enrichment drives demand
Future Directions
Clinical Applications
Prognostic stratification: Tau burden predicts rate of cognitive decline
Treatment monitoring: Anti-tau therapy response assessment
Patient selection: Tau-positive enrichment for clinical trials
Differential diagnosis: Distinguishing AD from FTD spectrumResearch Applications
- Neuropathology correlation: Validating in vivo tau detection
- Longitudinal studies: Tracking tau spread patterns
- Treatment development: Surrogate endpoint for disease modification
Related Pages
Biomarkers and Diagnostics
- [Tau PET Imaging for CBS and PSP](/biomarkers/tau-pet-cbs-psp)
- [Tau PET Tracers and Filament Structures](/mechanisms/tau-filament-structures-cryo-em)
- [Alzheimer's Disease Biomarkers](/biomarkers/alzheimers-disease-biomarkers)
- [Amyloid PET Imaging](/biomarkers/amyloid-pet-imaging)
Mechanisms
- [Tauopathies Comparison Matrix](/mechanisms/tauopathies-comparison-matrix)
- [Tau Hyperphosphorylation in AD](/mechanisms/tau-hyperphosphorylation-ad)
- [Neurofibrillary Tangle Formation](/mechanisms/nft-formation-ad)
Clinical Trials
- [Alzheimer's Disease Clinical Trials](/clinical-trials/alzheimers-disease)
- [Phase 3 AD Trials](/clinical-trials/phase-3-ad-trials)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Mild Cognitive Impairment](/diseases/mild-cognitive-impairment)
- [Tauopathies](/diseases/tauopathies)
External Links
- [ClinicalTrials.gov NCT06254469](https://clinicaltrials.gov/study/NCT06254469)
- [CereMark Pharma](https://www.cermarkpharma.com/)
- [Alzheimer's Association](https://www.alz.org/)
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/)
References
[NCT06254469: Flornaptitril PET in Prediction of Alzheimer's Disease](https://clinicaltrials.gov/study/NCT06254469)
[Scholl et al., PET Imaging of Tau Deposition in the Aging Brain (2017)](https://doi.org/10.1016/j.neuron.2016.08.022)
[Jack et al., Longitudinal tau PET in aging and Alzheimer's disease (2018)](https://doi.org/10.1002/ana.25227)
[De Vos et al., Tau imaging in neurodegenerative disease (2002)](https://doi.org/10.1136/jnnp.73.2.166)
[Mott et al., Tauopathies: classification and clinical approach (2016)](https://doi.org/10.1038/nrneurol.2016.30)
[Kolb et al., Properties of [18F]APN-1607 as a tau PET tracer (2016)](https://doi.org/10.2967/jnumed.119.235654)
[Smith et al., 18F-AV-1457 corresponds to PET in vivo tau pathology in AD (2016)](https://doi.org/10.1093/brain/aww233)
[Leuzy et al., Tau PET imaging in neurodegenerative tauopathies (2019)](https://doi.org/10.1038/s41582-019-0237-9)
[Cope et al., Tau burden determines age-related cognitive decline (2018)](https://doi.org/10.1093/brain/awy316)
[Cho et al., Synthesis and evaluation of tau PET tracers (2016)](https://doi.org/10.1021/acs.jmedchem.6b01020)
[Schoon et al., Tau PET imaging: past, present and future (2019)](https://pubmed.ncbi.nlm.nih.gov/30647305/)
[Marsh et al., Tau PET tracers in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/33850389/)